NCT06989957 Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD) Status RECRUITING Phase PHASE1
NCT06789705 Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls Status RECRUITING Phase NA
NCT06353282 MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents Status WITHDRAWN Phase PHASE2
NCT05837845 MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder Status RECRUITING Phase PHASE2
NCT05709353 MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder Status RECRUITING Phase PHASE2
NCT05584826 MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other Status RECRUITING Phase PHASE2
NCT05455996 MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers and First Responders Status NOT_YET_RECRUITING Phase PHASE2
NCT05379959 Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function Status COMPLETED Phase EARLY_PHASE1
NCT05067244 A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD) Status COMPLETED Phase PHASE2